Institut de Recerca Vall d'Hebron
Contacto correo-e: joan.sayos@vhir.org
El Grupo de Immunobiología del Centro en Investigación en Bioquímica y Biología Molecular para Nanomedicina (CIBBIM-Nanomedicina) del Institut de Recerca Hospital Universitari Vall d’Hebron en Barcelona busca candidatos para solicitar un contrato predoctoral AGAUR 2012.
Los candidatos han de cumplir uno de los requisitos de acceso al doctorado previstos en el RD 99/2011, de 28 de enero, que no tengan el título de doctor/a con las precisiones siguientes:
- Los estudios de máster o equivalente deben haber finalizado entre el 1 de enero de 2010 y el 31 de diciembre de 2012.
- En el caso de los estudios de grado con una extensión mínima de 300 ECTS, los solicitantes han de estar en posesión del titulo de grado en el momento de presentar la solicitud.
- También pueden ser solicitantes las personas físicas en posesión del título de licenciatura, ingeniería, o arquitectura superior que hayan obtenido la suficiencia investigadora (DEA) después del 1 de enero de 2010.
La Tesis Doctoral se desarrollará dentro del proyecto de Investigación “Inmuno receptores CD300; Caracterización funcional e implicación en enfermedades inflamatorias desmielinizantes”.
El plazo final para solicitar la beca es el día 12 de septiembre de 2012.
Interesados enviar CV a Dr. Joan Sayos (joan.sayos@vhir.org)
Información complementaria de la oferta:
Información sobre el proyecto de Investigación
The CD300family of immunoreceptors is composed by six members, CD300a/IRP60, CD300b/IREM3, CD300c/CMRF35, CD300d, CD300e/IREM2 and CD300f/IREM1. All of them share an extracellular region comprising a single Ig-like domain and, with the exception of CD300a, a myeloid linage restricted pattern of expression. In addition to the expression on myeloid cells, CD300a is found in some subsets of T, B and NK cells. The Immunobiology group is focused on the study of the structure and function of the CD300 family of immune receptors, as well as in their involvement in different human pathologies.
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (SNS) that affects more than 2.5 million individuals worldwide. The first symptoms appear between 20 and 30 years and is the main neurological disease in young adults, with higher incidence in women. Although the mechanisms underlying MS pathogenesis are still unclear, it is well known that patients' blood-brain barrier allows the passage of macrophages and lymphocytes to the NHS thereby initiating an inflammatory process. This inflammatory response includes activation of microglial cells and autoimmune attack against white matter oligodendrocytes. We propose, based on previous experimental data, the study of the role of the CD300f in the pathophysiology of this disease. First, we are working in the identification of the physiological ligand for this receptor, that we know is expressed by certain cells in the SNS. Secondly, the analysis of the role of soluble forms of CD300f in the
development of the disease by studying their expression in fluid samples of multiple sclerosis patients. Since activation of microglia and macrophages is critical in the development and expansion of MS lesions, the study of the mechanisms that regulate the activation of these cells may be of vital importance in the development of new therapeutic agents for the treatment of this disease.
Publicaciones recientes del Grupo de Investigación sobre el tema
Comas-Casellas E, Martínez-Barriocanal A, Ejarque-Ortiz, A, Miro, F, Schwartz S Jr, Martín M, and Sayós J. CD300d is a new member of the CD300 family of receptors that regulates their surface expression. J Biol Chem. 287: 9682-9693. (2012)
Peluffo, H, Alí-Ruiz, D, Ejarque-Ortíz, A, Heras-Alvarez, V, Comas-Casellas, E, Martínez-Barriocanal, A, Kamaid, A, Alvarez-Errico, D, Negro, ML, Lago, N, Schwartz Jr, S, Villaverde, A and Sayós, J. Overexpression of the immunoreceptor CD300f has a neuroprotective role in a model of acute brain injury. Brain Pathol. 22:318-328. (2012)
Martínez-Barriocanal A, Comas-Casellas E, Schwartz S Jr, Martín M, and Sayós J. CD300 heterocomplexes, a new and family-restricted mechanism for myeloid cell signaling regulation. J. Biol. Chem. 285:41781-94. (2010).
No comments:
Post a Comment